SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following strong 52-week VELA trial results that demonstrate clinical superiority and durability, fueling community speculation about a potential buyout. Investors are actively discussing the company's best-in-class profile and upcoming regulatory milestones, with many viewing the asset as a prime candidate for acquisition by a major pharmaceutical firm.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending due to active discussions regarding its undervalued position and potential as an acquisition target, further fueled by high-profile insider buying and speculation about strategic partnerships. Community sentiment remains polarized between long-term investors highlighting deep-value metrics and buybacks, and skeptics who express significant frustration over management performance and stagnant price action.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is seeing significant volatility after the FDA placed a clinical hold on its RGX-111 Hurler syndrome program and the related RGX-121 study due to a reported brain tumor, raising concerns about the safety of its common AAV9 gene therapy platform ahead of an upcoming PDUFA date. While analysts at Leerink have characterized the subsequent sell-off as an overreaction based on the program's limited financial contribution to the broader pipeline, community discourse remains split between those viewing the pullback as a buying opportunity and others bracing for a potential Complete Response Letter regarding the pending RGX-121 application.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is seeing increased investor attention as the market anticipates topline results from its Phase 3 Emerge trial for MDD and subsequent GAD data readouts later this year. The community is actively debating the company's clinical prospects and cash runway, while closely watching for potential regulatory catalysts like priority vouchers in the broader psychedelics sector.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is trending as investors rally around a significant $2 billion convertible senior notes offering, with the community highly focused on the company's strategic use of proceeds for share repurchases and aggressive global expansion. Traders are closely monitoring the stock's reclaim of key technical moving averages, fueling intense debate between long-term bulls betting on ecosystem growth and day traders navigating sharp intraday volatility.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is trending due to significant institutional interest surrounding its pivot toward AI-focused power infrastructure and the anticipation of upcoming hyperscaler lease announcements. The community is actively discussing the stock's potential for a valuation re-rating, with traders highlighting recent technical momentum and the firm's strategic positioning ahead of index fund inflows.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda to advance solid-state battery development and manufacturing processes. The community is actively discussing whether this partnership marks a major milestone for the companys commercial viability, with many investors debating the long-term potential for expansion into broader sectors like robotics and AI data centers.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors weigh strong DefenCath utilization and raised revenue guidance against ongoing concerns regarding the impending TDAPA reimbursement cliff and the company's long-term growth strategy. While bulls highlight institutional support and successful patent litigation, the community remains divided over management's execution and the timeline for realizing potential from the Melinta portfolio and pipeline assets.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber, Inc. is trending as investors aggressively rotate into AI infrastructure and compute proxies, with the stock drawing significant attention due to its low float and strategic alignment as a partner for high-profile AI chip deployments. Community sentiment is heavily focused on the company's upcoming earnings report and the broader hype surrounding the Cerebras IPO, with many traders discussing potential short squeeze mechanics and long-term data-center capacity value.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is generating intense community discussion due to ongoing speculation surrounding a potential partnership with POSCO and the impact of fluctuating HRC steel prices on the company's valuation. Investors remain deeply divided, with some betting on a short squeeze fueled by significant short interest while others express frustration over management, debt levels, and the stock's sensitivity to broader market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026...

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the Company or Delcath), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Companys Compensation Committee, as material...

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New...

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems (DCTH) delivered earnings and revenue surprises of -200.00% and -0.42%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective...

Delcath Systems (DCTH) to Release Quarterly Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-delcath-systems-inc-stock...

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026...

Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the com...

JPMorgan Chase & Co. Decreases Position in Delcath Systems, Inc. $DCTH

JPMorgan Chase & Co. cut its position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 92.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 12,501 shares of the company's stock after selling 155,744 shares during the period. JPMorgan Chase & Co.'s ho...

Delcath Systems (NASDAQ:DCTH) Stock Price Up 0.3% - Time to Buy?

Delcath Systems (NASDAQ:DCTH) Shares Up 0.3% - Should You Buy...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

DCTHDelcath Systems Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DCTH News